Form 4: Immunome CSO Exercises Options, Acquires 22,000 Shares

Immunome's Chief Scientific Officer, Jack Higgins, exercised stock options to acquire 22,000 shares of common stock at $1.35 per share.

Summary

• Jack Higgins, Chief Scientific Officer of Immunome Inc. (IMNM), exercised employee stock options on September 10, 2025.
• The transaction involved the acquisition of 22,000 shares of Immunome common stock.
• The exercise price for these options was $1.35 per share.
• Following this transaction, Mr. Higgins directly owns 40,729 shares of common stock.
• After the exercise, Mr. Higgins retains 151,840 derivative securities (employee stock options).
• The options exercised were part of a grant where 25% vested on May 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, and have an expiration date of June 23, 2032.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. An insider exercising options, especially a Chief Scientific Officer, suggests confidence in the company's future and the value of its stock. It's a routine transaction but carries a positive signal.

Positives

• The exercise of stock options by a Chief Scientific Officer can signal confidence in the company's future prospects and valuation.
• The exercise price of $1.35 is significantly below the current market price, indicating a potential profit for the insider, which aligns their interests with shareholders.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the exercise of options by a key executive can be interpreted as a positive signal regarding future company performance.

Industry Context

Insider transactions, such as option exercises, are common in the biotechnology and pharmaceutical sectors, where executive compensation often includes significant equity components. Such exercises can reflect an executive's belief in the long-term value of their company's pipeline or market position.

Comparison to Industry Standards

• The exercise of stock options by a Chief Scientific Officer is a standard practice for executive compensation in the biotech industry, aligning executive incentives with shareholder value creation.
• The exercise price of $1.35 per share, compared to the market price at the time of exercise (not explicitly stated but implied to be higher for a profitable exercise), is typical for options granted at a lower strike price, often at the grant date's market value.

Related Party Transactions

• The transaction is a related party transaction as it involves the exercise of stock options by a Chief Scientific Officer, an insider of Immunome Inc.

Stakeholder Impact

• Shareholders: The transaction may be viewed positively as it indicates an executive's continued investment and confidence in the company, potentially bolstering investor sentiment.
• Employees: The exercise of options by a senior executive can serve as a positive example or signal regarding the value of employee equity compensation programs.

Key Dates

Recommendation

While the insider's option exercise is a positive signal, a single Form 4 filing typically does not provide enough comprehensive information to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' position for existing investors, suggesting continued confidence from management, but does not introduce new fundamental data to change a broader investment thesis.

Keywords

Immunome Inc., IMNM, Jack Higgins, Chief Scientific Officer, Stock Options, Insider Transaction, Form 4, Equity Acquisition, Biotechnology, Pharmaceutical